Rapport Therapeutics, Inc. Common Stock
Rapport Therapeutics, Inc. Common Stock（RAPP）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · RAPP · 截至 2025年9月30日
股东结构概览
133
机构持有人数
▲ 51 vs Q2
$1.46B
机构持仓总市值
▲ $1.03B vs Q2
36.50M
总流通股
freeFloat 47.84%
49.28M
13F 申报持股数
▲ 10.78M vs Q2
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
RAPP 最大股东 · 机构持仓
Q3 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
TRV GP V, LLC pharmaceutical preparations | 7.14M | 2.01% | 2.01% | $211.92B | Nov 13, 2025 | — held |
FMR LLC pharmaceutical preparations | 6.92M | 1.95% | 1.95% | $205.43B | Nov 13, 2025 | ▲ 1.44M |
ARCH VENTURE MANAGEMENT, LLC pharmaceutical preparations | 3.73M | 1.05% | 1.05% | $110.74B | Nov 14, 2025 | — held |
CAPITAL INTERNATIONAL INVESTORS pharmaceutical preparations | 3.40M | 96.00% | 96.00% | $101.06B | Nov 13, 2025 | ▲ 800.0K |
CORMORANT ASSET MANAGEMENT, LP pharmaceutical preparations | 3.19M | 90.07% | 90.07% | $94.82B | Nov 14, 2025 | ▲ 251.6K |
GOLDMAN SACHS GROUP INC pharmaceutical preparations | 2.42M | 68.33% | 68.33% | $71.93B | Nov 14, 2025 | ▲ 1.19M |
SOFINNOVA INVESTMENTS, INC. pharmaceutical preparations | 1.95M | 54.95% | 54.95% | $57.84B | Nov 14, 2025 | ▼ 48.0K |
JOHNSON & JOHNSON pharmaceutical preparations | 1.78M | 50.35% | 50.35% | $53.00B | Mar 18, 2026 | ▼ 713.5K |
VANGUARD GROUP INC pharmaceutical preparations | 1.63M | 45.89% | 45.89% | $48.31B | Nov 7, 2025 | ▲ 519.0K |
BLACKROCK, INC. pharmaceutical preparations | 1.57M | 44.24% | 44.24% | $46.57B | Nov 12, 2025 | ▲ 348.9K |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q3 2025 对比上季度
Q3 2025
18
增持
+8.02M 股22
新建仓
首次建仓6
减持
−1.56M 股0
清仓
完全退出净股数变化（前50家）
+6.46M
+8.02M / −1.56M
净新增持仓人
+34
新建 22 个 / 退出 0 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
RAPP 内幕交易记录
数据来源：SEC Form 4
近期内部人员以卖出为主。 卖出可能源于预定的 10b5-1 计划，不代表负面展望。
0
买入笔数
10
卖出笔数
0.00
买卖比
$1M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
Third Rock Ventures V, L.P. 10 percent owner | May 26, 2026 | Sale | 18,572 | $40.05 | $743.8K | 6.28M | Form 4 ↗ |
Third Rock Ventures V, L.P. 10 percent owner | May 11, 2026 | Sale | 133,618 | $40.24 | $5.38M | 6.30M | Form 4 ↗ |
Third Rock Ventures V, L.P. 10 percent owner | May 7, 2026 | Sale | 271,495 | $40.12 | $10.89M | 6.44M | Form 4 ↗ |
Third Rock Ventures V, L.P. 10 percent owner | May 8, 2026 | Sale | 5,018 | $40.31 | $202.3K | 6.43M | Form 4 ↗ |
Third Rock Ventures V, L.P. 10 percent owner | Apr 17, 2026 | Sale | 426,005 | $40.32 | $17.18M | 6.71M | Form 4 ↗ |
Yeleswaram Krishnaswamy Chief Development Officer | Apr 17, 2026 | Sale | 20,225 | $39.99 | $808.8K | 246.4K | Form 4 ↗ |
Yeleswaram Krishnaswamy Chief Development Officer | Apr 10, 2026 | Sale | 500 | $34.98 | $17.5K | 286.0K | Form 4 ↗ |
Yeleswaram Krishnaswamy Chief Development Officer | Apr 13, 2026 | Sale | 9,165 | $34.97 | $320.5K | 276.9K | Form 4 ↗ |
Yeleswaram Krishnaswamy Chief Development Officer | Apr 14, 2026 | Sale | 10,200 | $35.08 | $357.8K | 266.7K | Form 4 ↗ |
Yeleswaram Krishnaswamy Chief Development Officer | Apr 8, 2026 | Sale | 360 | $34.90 | $12.6K | 286.5K | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
Rapport Therapeutics, Inc. Common Stock（RAPP）主要由机构投资者持有，机构持股比例约为 100.0%。公司内部人员持股约 52.16%，散户及公众持股约占剩余的 0.00%。
Rapport Therapeutics, Inc. Common Stock 最大机构股东为 TRV GP V, LLC，截至 September 30, 2025 持有约 7.14 million 股，占总流通股的 2.01%。
目前共有 133 家机构持有 RAPP 股票，合计持仓市值约 $1.46 billion，数据来源为最新 SEC 13F 申报。
常见问题
RAPP ownershipRapport Therapeutics, Inc. Common Stock（RAPP）主要由机构投资者持有，机构持股约 100.0%。最大股东为 TRV GP V, LLC，持股比例 2.01%。内部人员持股约 52.16%。数据来源 SEC Form 13F，截至 September 30, 2025。